Before considering irreversible ovarian surgery for severe PMDD, ask a narrower question: do symptoms improve when ovarian cycling is suppressed—and does that remain true with a realistic plan for hormone add-back? A GnRH agonist trial can help answer that question. It is a treatment trial and an imperfect guide to surgical response, not a validated stand-alone diagnostic test.
That distinction matters when a patient has tried antidepressants and a combined hormonal contraceptive. The medication names alone do not establish that each trial was adequate; dose, duration, adherence, treatment target, benefit, and adverse effects still need review. If symptoms remain disabling after appropriate care, ACOG suggests GnRH agonists with combined hormonal add-back therapy for adults with severe, refractory premenstrual symptoms.
Suppress the cycle; don’t mistake that for “fixing” a hormone level
PMDD is not generally understood as an excess or deficiency of ovarian hormones. A leading theory is that some people have heightened sensitivity to normal changes in estrogen and progesterone across the cycle. A GnRH agonist suppresses pituitary signaling to the ovaries, inducing anovulation and reducing the cyclic hormonal changes that can trigger symptoms.
This is reversible medical suppression—not a literal “medical oophorectomy.” It differs from surgery, which permanently removes ovarian function. A hysterectomy that leaves the ovaries in place also does not, by itself, stop ovarian cycling.
The trial is most informative when the target is clear. To confirm PMDD, DSM-5-TR calls for prospective daily symptom ratings during at least two symptomatic cycles; a provisional diagnosis can be made before that confirmation. Review the symptom pattern across the whole cycle, including any lower-symptom interval, and establish baseline function: work or school participation, relationships, self-care, and other activities affected. Persistent symptoms that worsen before menses may reflect premenstrual exacerbation of another disorder rather than PMDD alone; ovarian suppression may reduce the cyclic peak without treating the underlying condition.
Decide what the trial is meant to predict
A pre-surgical trial asks whether suppressing ovarian cycling substantially improves the symptoms and functional impairment the patient wants treated. Agree in advance on the measures: daily symptom ratings, such as the Daily Record of Severity of Problems, plus concrete functional goals. Assess safety, including suicidal thoughts or behavior when clinically indicated, and make a plan for urgent changes rather than waiting for the trial to end.
A monitored trial is usually planned with gynecology or another clinician experienced in hormonal treatment, alongside psychiatric follow-up when mood symptoms are prominent. ACOG notes that two to three months is generally sufficient to see whether a treatment response is emerging, while individual circumstances may affect how the trial is managed. ACOG also advises considering a GnRH-agonist trial before surgery to help predict response to surgical management.
When surgery is under consideration, assessing symptoms with a feasible add-back plan can make the trial more relevant to expected postoperative management. Add-back therapy can reduce harms of low estrogen, such as vasomotor symptoms and decreased bone density. Because adding hormones can also bring symptoms back for some patients, the regimen and symptom timeline need to be interpreted together. One small study observed recurrence during the first month of combined add-back that subsided over the following two months. An early increase after starting add-back does not automatically mean suppression failed; it does warrant review with the treating specialist, not an assumption that the patient should simply endure it.
| What the trial shows | What it may suggest | What it does not prove |
|---|---|---|
| Clear, sustained improvement in the target symptoms and function during suppression | Symptoms have a substantial ovarian-cycle-linked component; permanent ovarian suppression might help | That surgery will reproduce the same result or resolve every psychiatric symptom |
| Improvement in the premenstrual peak, with symptoms still present across the cycle | A cyclical component may coexist with a baseline mood or other disorder | That the entire presentation is PMDD, or that persistent symptoms are treatment failure |
| Little improvement despite an adequate, monitored trial | Revisit the formulation, functional goals, and whether this treatment target is likely to help | That PMDD is automatically excluded, or that the trial was adequate without checking the details |
| Symptoms worsen around add-back | The added hormone exposure or its timing may matter; review the regimen and course | That ovarian suppression was ineffective or the original diagnosis was wrong |
Use the result as evidence, not a verdict
A strong response supports the idea that ovarian cycling contributes to the patient’s symptoms and gives useful information for a discussion about bilateral oophorectomy. But the prediction is imperfect: randomized trials have not established the effectiveness of oophorectomy for premenstrual disorders, and the surgical rationale draws partly on evidence from ovarian suppression.
A weak or absent response should prompt questions before a conclusion: Was the intended suppression achieved? Was the observation period sufficient? Did persistent symptoms reflect a co-occurring or alternative disorder? Did symptoms change during add-back? Recheck the prospective record and baseline history. Do not let a single trial response substitute for clinical formulation.
The hormone plan after surgery matters too. Oophorectomy causes permanent ovarian hormone loss, so counseling should cover the likely need for hormone therapy and the health effects of early hypoestrogenism. If the uterus remains, estrogen-only therapy can carry endometrial risks; progestogen-containing add-back may also bring symptoms back for some patients. Whether hysterectomy is part of a surgical plan is therefore a separate, individualized decision—not an automatic requirement for PMDD.
Practical takeaways
- Use GnRH suppression as a treatment-response and pre-surgical prediction trial, not as a validated diagnostic test.
- Establish prospective symptom patterns, baseline function, and specific goals before the trial.
- Interpret improvement, persistent background symptoms, nonresponse, and add-back effects separately.
- A favorable response supports discussing surgery; it does not guarantee surgical success or resolve co-occurring disorders.
- Keep decisions about ovarian removal, hysterectomy, and hormone add-back individualized and collaborative.
